526 related articles for article (PubMed ID: 34067474)
1. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
3. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
6. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.
Eftekhar SP; Yazdanpanah N; Rezaei N
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1211-1228. PubMed ID: 34511008
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review.
Chitsazan M; Amin A; Ladel L; Baig A; Chitsazan M
Crit Pathw Cardiol; 2023 Sep; 22(3):69-82. PubMed ID: 37363862
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
Ma R; Wang Q; Meng D; Li K; Zhang Y
BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
17. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.
de La Rochefoucauld J; Noël N; Lambotte O
Intern Emerg Med; 2020 Jun; 15(4):587-598. PubMed ID: 32144552
[TBL] [Abstract][Full Text] [Related]
18. Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration.
Liu Z; Fan Y; Guo J; Bian N; Chen D
ESC Heart Fail; 2022 Jun; 9(3):2020-2026. PubMed ID: 35322589
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
20. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
